Waldron Private Wealth LLC Acquires 1,282 Shares of Novo Nordisk A/S (NYSE:NVO)

Waldron Private Wealth LLC boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 44.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,141 shares of the company’s stock after purchasing an additional 1,282 shares during the period. Waldron Private Wealth LLC’s holdings in Novo Nordisk A/S were worth $493,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NVO. RMR Wealth Builders bought a new position in shares of Novo Nordisk A/S in the 1st quarter valued at $302,000. Future Financial Wealth Managment LLC bought a new position in shares of Novo Nordisk A/S in the 1st quarter valued at $128,000. Sunpointe LLC lifted its stake in shares of Novo Nordisk A/S by 5.8% in the 1st quarter. Sunpointe LLC now owns 6,757 shares of the company’s stock valued at $874,000 after acquiring an additional 372 shares during the last quarter. DGS Capital Management LLC lifted its stake in shares of Novo Nordisk A/S by 2.8% in the 1st quarter. DGS Capital Management LLC now owns 42,888 shares of the company’s stock valued at $5,507,000 after acquiring an additional 1,151 shares during the last quarter. Finally, S.A. Mason LLC lifted its stake in shares of Novo Nordisk A/S by 33.7% in the 1st quarter. S.A. Mason LLC now owns 9,628 shares of the company’s stock valued at $1,236,000 after acquiring an additional 2,428 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $116.46 on Wednesday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.46. The business has a 50-day moving average price of $127.89 and a two-hundred day moving average price of $131.61. Novo Nordisk A/S has a 1-year low of $92.94 and a 1-year high of $148.15. The company has a market cap of $522.62 billion, a P/E ratio of 39.88, a PEG ratio of 1.54 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. The business had revenue of $9.82 billion for the quarter, compared to analyst estimates of $9.91 billion. As a group, analysts anticipate that Novo Nordisk A/S will post 3.01 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were paid a $0.5126 dividend. The ex-dividend date was Friday, August 16th. This represents a dividend yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio is presently 24.66%.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of research reports. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 9th. BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, October 10th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.